Ocumension Therapeutics (HK:1477) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ocumension Therapeutics has announced the approval of its new antihistamine eye drop, OT-1001 (Zerviate), by China’s National Medical Products Administration for treating ocular itching associated with allergic conjunctivitis. The medication, which is already in use in the United States, presents a novel treatment option for patients in the Greater China region. However, the company cautions that there is no guarantee of successful marketing in the future.
For further insights into HK:1477 stock, check out TipRanks’ Stock Analysis page.